## CLAIMS

1 . A liquid pharmaceutical composition comprising 50-250 mg/mL immunoglobulins in 250 mM glycine 0.02% (w/v) polysorbate 20 at a pH of 4 – 7, wherein at least 50% of branched glycans on the Fc region of the immunoglobulins are disialylated by way of NeuAc-a 2,6-Gal terminal linkages, wherein the liquid pharmaceutical composition is agitation stable to forming particles.

2. The liquid pharmaceutical composition of claim 1, wherein the concentration of immunoglobulins is 70-130 mg/mL.

3. The liquid pharmaceutical composition of claim 1, wherein the concentration of immunoglobulins is 80-120 mg/mL.

4. The liquid pharmaceutical composition of claim 1, wherein the concentration of immunoglobulins is 90-1 10 mg/mL.

5. The liquid pharmaceutical composition of any of claims 1-4, wherein at least 60%, 70%, 80%, 90% or 95% of branched glycans on the Fc domain of the immunoglobulins are disialylated by way of NeuAc-a 2,6-Gal terminal linkages.

6. The liquid pharmaceutical composition of any of claims 1-5, wherein at least 60%, 70%, 80%, 90% or 95% of branched glycans on the immunoglobulins are disialylated by way of NeuAc-a 2,6-Gal terminal linkages.

7. The liquid pharmaceutical composition of any of claims 1-6, wherein at least 60%, 70%, 80%, 90% or 95% of branched glycans on the Fab domain of the immunoglobulins are disialylated by way of NeuAc-a 2,6-Gal terminal linkages.

8. The liquid pharmaceutical composition of any of claims 1-7, wherein at least 90% of the immunoglobulins are IgG immunoglobulins.

9. The liquid pharmaceutical composition of claim 8, wherein at least 95% of the immunoglobulins are IgG immunoglobulins.

10. The liquid pharmaceutical composition of any of claims 1-9, wherein 5-20% of the immunoglobulins are dimers.

11. The liquid pharmaceutical composition of any of claims 1-10, wherein 5-10% of the immunoglobulins are dimers.

12. The liquid pharmaceutical composition of any of claims 1-11, wherein at least 80% of the immunoglobulins are monomers or dimers.

13. The liquid pharmaceutical composition of claim 12, wherein at least 85% of the immunoglobulins are monomers or dimers.

14. The liquid pharmaceutical composition of claim 12, wherein at least 90% of the immunoglobulins are monomers or dimers.

15. The liquid pharmaceutical composition of any of claims 1-14, wherein 5-20% of the IgG immunoglobulins are dimers.

16. The liquid pharmaceutical composition of claim 15, wherein 5-10% of the IgG immunoglobulins are dimers.

17. The liquid pharmaceutical composition of any of claims 1-16, wherein at least 80% of the IgG immunoglobulins are monomers or dimers.

18. The liquid pharmaceutical composition of claim 17, wherein at least 85% of the IgG immunoglobulins are monomers or dimers.

19. The liquid pharmaceutical composition of claim 17, wherein at least 90% of the IgG immunoglobulins are monomers or dimers.

20. The liquid pharmaceutical composition of any of claims 1-19, wherein at least 60%, 70%, 80%, 90% or 95% of branched glycans on the Fc domain of the IgG immunoglobulins are disialylated by way of NeuAc-a 2,6-Gal terminal linkages.

21. The liquid pharmaceutical composition of any of claims 1-20, wherein at least 60%, 70%, 80%, 90% or 95% of branched glycans on the IgG immunoglobulins are disialylated by way of NeuAc-a 2,6-Gal terminal linkages.

22. The liquid pharmaceutical composition of any of claims 1-21, wherein at least 60%, 70%, 80%, 90% or 95% of branched glycans on the Fab domain of the IgG immunoglobulins are disialylated by way of NeuAc-a 2,6-Gal terminal linkages.

23. The liquid pharmaceutical composition of claim 1, wherein the pH is 4.7 - 5.5.

24. The liquid pharmaceutical composition of claim 1, wherein the pH is 5.1 - 5.3.

25. The liquid pharmaceutical composition of any of claims 1-24, wherein the composition has fewer than 1000 particles with a diameter between 10 and 100 micrometers after agitation at 1000 RPM for 8 hours at 2-8 °C per mL of the composition.

26. The liquid pharmaceutical composition of any of claims 1-25, wherein the composition has fewer than 500 particles with a diameter between 10 and 100 micrometers after agitation at 1000 RPM for 8 hours at 2-8 °C per mL of the composition.

27. The liquid pharmaceutical composition of any of claims 1-26, wherein the composition has fewer than 200 particles with a diameter between 10 and 100 micrometers after agitation at 1000 RPM for 8 hours at 2-8 °C per mL of the composition.

28. The liquid pharmaceutical composition of any of claims 1-27, wherein at least 60%, 70%, 80%, 90% or 95% of branched glycans on the Fc domain of the immunoglobulins are disialylated by way of NeuAc-a 2,6-Gal terminal linkages after storage for 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22 or 24 months at 4°C.

29. The liquid pharmaceutical composition of any of claims 1-28, wherein at least 60%, 70%, 80%, 90% or 95% of branched glycans on the immunoglobulins are disialylated by way of NeuAc-a 2,6-Gal terminal linkages after storage for 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22 or 24 months at 4°C.

30. The liquid pharmaceutical composition of any of claims 1-29, wherein at least 60%, 70%, 80%, 90% or 95% of branched glycans on the Fab domain of the immunoglobulins are disialylated by way of NeuAc-a 2,6-Gal terminal linkages after storage for 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22 or 24 months at 4°C.

31. The liquid pharmaceutical composition of any of claims 1-30, wherein at least 5-10% of the immunoglobulins are dimers after storage for 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22 or 24 months at 4°C.

32. The liquid pharmaceutical composition of any of claims 1-31, wherein at least 85% of the immunoglobulins are monomers or dimers after storage for 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22 or 24 months at 4°C.

33. The liquid pharmaceutical composition of any of claims 1-32, wherein at least 90% of the immunoglobulins are monomers or dimers after storage for 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22 or 24 months at 4°C.

34. The liquid pharmaceutical composition of any of claims 1-33, wherein the liquid pharmaceutical composition is stable at 5°C for at least 7 months, at 25°C at least one month, at 2-8°C for at least two years and/or for at least two weeks at 15-30°C.

35. The liquid pharmaceutical composition of any of claims 25-34, wherein the liquid pharmaceutical composition is stored in a sealed hydrolytic-resistant glass vial.

36. The liquid pharmaceutical composition of any of claims 25-34, wherein the liquid pharmaceutical composition is stored in a sealed a pharmaceutical-grade tubular hydrolytic-resistant glass injection vial.